Decreased autophagosome biogenesis, reduced NRF2, and enhanced ferroptotic cell death are underlying molecular mechanisms of non-alcoholic fatty liver disease

被引:35
|
作者
Liu, Pengfei [1 ,2 ,3 ]
Anandhan, Annadurai [1 ]
Chen, Jinjing [1 ]
Shakya, Aryatara [1 ]
Dodson, Matthew [1 ]
Ooi, Aikseng [1 ]
Chapman, Eli [1 ]
White, Eileen [4 ]
Garcia, Joe G. N. [5 ,6 ]
Zhang, Donna D. [1 ,7 ,8 ]
机构
[1] Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA
[2] Xi An Jiao Tong Univ, Natl & Local Joint Engn Res Ctr Biodiag & Biothera, Affiliated Hosp 2, Xian, Peoples R China
[3] Xi An Jiao Tong Univ, Int Joint Res Ctr Cell Stress & Dis Diag & Therapy, Affiliated Hosp 2, Xian, Peoples R China
[4] Rutgers Canc Inst New Jersey, Dept Mol Biol & Biochem, New Brunswick, NJ USA
[5] Univ Arizona, Dept Med, Tucson, AZ 85721 USA
[6] Univ Arizona, Arizona Hlth Sci Ctr, Tucson, AZ 85721 USA
[7] Univ Arizona, Univ Arizona Canc Ctr, Tucson, AZ 85721 USA
[8] Univ Arizona, Coll Pharm, 1703 E Mabel St, Tucson, AZ 85721 USA
来源
REDOX BIOLOGY | 2023年 / 59卷
基金
美国国家卫生研究院;
关键词
NRF2; KEAP1; High fat diet; Autophagy; Ferroptosis; Liver steatosis; NAFLD; ATG7; mTOR; AKT; AMPK; Fatty acids; TRANSCRIPTION FACTOR NRF2; OXIDATIVE STRESS; KEAP1; PROTEIN; STEATOHEPATITIS; INACTIVATION; DEGRADATION; ACTIVATION; REGULATOR; PATHWAY;
D O I
10.1016/j.redox.2022.102570
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background and aims: Caloric excess and sedentary lifestyles have led to an epidemic of obesity, metabolic syndrome, and non-alcoholic fatty liver disease (NAFLD). The objective of this study was to investigate the mechanisms underlying high fat diet (HFD)-induced NAFLD, and to explore NRF2 activation as a strategy to alleviate NAFLD.Approach and results: Herein, we demonstrated that high fat diet (HFD) induced lipid peroxidation and ferrop-tosis, both of which could be alleviated by NRF2 upregulation. Mechanistically, HFD suppressed autophagosome biogenesis through AMPK-and AKT-mediated mTOR activation and decreased ATG7, resulting in KEAP1 sta-bilization and decreased NRF2 levels in mouse liver. Furthermore, ATG7 is required for HFD-induced NRF2 downregulation, as ATG7 deletion in Cre-inducible ATG7 knockout mice decreased NRF2 levels and enhanced ferroptosis, which was not further exacerbated by HFD. This finding was recapitulated in mouse hepatocytes, which showed a similar phenotype upon treatment with saturated fatty acids (SFAs) but not monounsaturated fatty acids (MUFAs). Finally, NRF2 activation blocked fatty acid (FA)-mediated NRF2 downregulation, lipid peroxidation, and ferroptosis. Importantly, the HFD-induced alterations were also observed in human fatty liver tissue samples. Conclusions: HFD-mediated autophagy inhibition, NRF2 suppression, and ferroptosis promotion are important molecular mechanisms of obesity-driven metabolic diseases. NRF2 activation counteracts HFD-mediated NRF2 suppression and ferroptotic cell death. In addition, SFA vs. MUFA regulation of NRF2 may underlie their harmful vs. beneficial effects. Our study reveals NRF2 as a key player in the development and progression of fatty liver disease and that NRF2 activation could serve as a potential therapeutic strategy.
引用
收藏
页数:14
相关论文
共 47 条
  • [1] Upregulation of Nrf2 Expression in Non-Alcoholic Fatty Liver and Steatohepatitis
    Xu, Weihua
    Shao, Luolin
    Zhou, Chengjun
    Wang, Hongbo
    Guo, Jianqiang
    HEPATO-GASTROENTEROLOGY, 2011, 58 (112) : 2077 - 2080
  • [2] Lactobacillus plantarum NA136 improves the non-alcoholic fatty liver disease by modulating the AMPK/Nrf2 pathway
    Zhao, Zijian
    Wang, Chao
    Zhang, Li
    Zhao, Yujuan
    Duan, Cuicui
    Zhang, Xue
    Gao, Lei
    Li, Shengyu
    APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, 2019, 103 (14) : 5843 - 5850
  • [3] Resveratrol alleviates non-alcoholic fatty liver disease through epigenetic modification of the Nrf2 signaling pathway
    Hosseini, Hossein
    Teimouri, Maryam
    Shabani, Maryam
    Koushki, Mehdi
    Khorzoughi, Reyhaneh Babaei
    Namvarjah, Fatemeh
    Izadi, Pantea
    Meshkani, Reza
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2020, 119
  • [4] Impact of Glucoraphanin-Mediated Activation of Nrf2 on Non-Alcoholic Fatty Liver Disease with a Focus on Mitochondrial Dysfunction
    Xu, Liang
    Nagata, Naoto
    Ota, Tsuguhito
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (23)
  • [5] Lactobacillus plantarum NA136 improves the non-alcoholic fatty liver disease by modulating the AMPK/Nrf2 pathway
    Zijian Zhao
    Chao Wang
    Li Zhang
    Yujuan Zhao
    Cuicui Duan
    Xue Zhang
    Lei Gao
    Shengyu Li
    Applied Microbiology and Biotechnology, 2019, 103 : 5843 - 5850
  • [6] Bioprotective Role of Phytocompounds Against the Pathogenesis of Non-alcoholic Fatty Liver Disease to Non-alcoholic Steatohepatitis: Unravelling Underlying Molecular Mechanisms
    Banerjee, Tanmoy
    Sarkar, Arnab
    Ali, Sk Zeeshan
    Bhowmik, Rudranil
    Karmakar, Sanmoy
    Halder, Amit Kumar
    Ghosh, Nilanjan
    PLANTA MEDICA, 2024, 90 (09) : 675 - 707
  • [7] Abscisic acid improves non-alcoholic fatty liver disease in mice through the AMPK/NRF2/KEAP1 signaling axis
    Zhang, Lin
    Du, Fu Hua
    Kun, Kai Xiao
    Yan, Yong
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2025, 747
  • [8] Berberine attenuates hepatic oxidative stress in rats with non-alcoholic fatty liver disease via the Nrf2/ARE signalling pathway
    Deng, Yuanjun
    Tang, Kairui
    Chen, Runsen
    Nie, Huan
    Liang, Shu
    Zhang, Jinwen
    Zhang, Yupei
    Yang, Qinhe
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2019, 17 (03) : 2091 - 2098
  • [9] Protective role of magnesium isoglycyrrhizinate in non-alcoholic fatty liver disease and the associated molecular mechanisms
    Xu, Qian
    Wang, Ji
    Chen, Feifei
    Lin, Kaisu
    Zhu, Mingao
    Chen, Lei
    Zhou, Xiumin
    Li, Chong
    Zhu, Hong
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2016, 38 (01) : 275 - 282
  • [10] CRISPR/Cas9-Based Screening of FDA-Approved Drugs for NRF2 Activation: A Novel Approach to Discover Therapeutics for Non-Alcoholic Fatty Liver Disease
    Li, James
    Arest, Sandra
    Olszowy, Bartlomiej
    Gordon, John
    Barrero, Carlos A.
    Perez-Leal, Oscar
    ANTIOXIDANTS, 2023, 12 (07)